Drug Stock Lifted by New Collaboration

Eton Pharmaceuticals is linking up with Xellia Pharmaceuticals

Patrick Martin

Managing Editor

Jan 21, 2020 at 10:06 AM

ETON

In the biotech sphere today, the big news is a co-promotional agreement between drugmakers Eton Pharmaceuticals Inc (NASDAQ:ETON) and privately held Xellia Pharmaceuticals. The two companies will team up to promote Biorphen, Eton's Food and Drug Administration (FDA) approved blood pressure treatment.

In response, Eton stock is up 3.2% to trade at $7.37. The shares have spent the start of 2020 consolidating below $7.50, with their 20-day moving average cushioning pullbacks below. Since a Sept. 5 bottom of $5.13, ETON has now tacked on 44%.

There hasn't been a peep from the analyst community in response to the agreement. But that may be because most analysts are firmly entrenched in the bullish camp, with all three in coverage doling out "buy" ratings. Plus, the consensus 12-month price target of $16.83 is a 135.7% premium to Friday's closing perch at $7.14.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.